The global Friedreich’s Ataxia market size was valued at USD 750 million in 2021 and is projected to reach around USD 2,060 million in 2030 exhibiting a CAGR of 12% in the forecasted period.
The fast research and development activities for manufacturing latest therapeutics for Friedreich's Ataxia treatment, rising inorganic business growth strategies such as acquisitions, collaborations, and others among market players, are expected to upsurge the market growth. However, problems faced during planning and conducting clinical trials for development of Freidreich's Ataxia treatment are projected to hinder the growth of the market in the forecasted period.
Growing research and development activities for manufacturing of new Friedreich’s ataxia therapeutics is estimated to drive the market growth over the forecasted period. For instance, as per an article published in the Neurobiology of Disease journal, in January 2021, an oral drug called leriglitazone had presented benefits in handling Friedrich's ataxia in cellular and animal models. Leriglitazone is produced by Minoryx Therapeutics which is presently in innovative Phase 2/3 of clinical trials for the cure of Friedrich's ataxia. Leriglitazone re-establishes mitochondrial function which is normally hindered owing to the deficiency of mitochondrial protein frataxin (FXN) in Friedreich's ataxia disease. Moreover, in February 2022, Design Therapeutics, Inc. announced that it is presently showing Phase 1 clinical trial of its investigational drug DT-216, an intravenous (IV) injection for the treatment of Friedreich's Ataxia and this clinical trial study is projected to be finalized by December 2022. Major players functioning in market are aiming on attaining regulatory approval of their Friedreich’s ataxia drugs, which is anticipated to drive growth of the global Friedreich’s ataxia market during the forecast period.
High burden of Friedreich’s ataxia is anticipated to drive growth of the Friedreich’s ataxia market across the forecasted period. For instance, as per the data published by the Ataxia UK, a charity registered in Scotland and England & Wales in November 2020, it was projected that the incidence of Friedreich’s ataxia established on carrier frequency of 1 in 85 was 1: 29,000 in Europe in 2020. Moreover, according to the research conducted till date, Friedreich’s Ataxia affects 1 in every 40,000 people.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus) was stated as a global pandemic by the World Health Organization (WHO), which describes this SARS-CoV-2 infection as novel Coronavirus (COVID-19). As per the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, COVID-19 has spread throughout the globe infecting more than 519 million population intending to over 6.3 million deaths as of May 15, 2022. The adverse impact of COVID-19 on the healthcare domain is vast and it has considerably disrupted the healthcare industries’ complete supply chain, from raw materials to development and delivery. Also, the COVID-19 pandemic had a negative impact on the overall growth of the Friedreich’s ataxia market, due to movement limitations and lockdowns.
Likewise, demand and supply for Friedreich’s ataxia therapeutics was disturbed, due to termination of clinical trials intended at developing treatment drugs for Freidreich’s ataxia, and disrupted supply of Friedreich’s ataxia treatment drugs through the lockdown. Furthermore, physiotherapy, rehabilitation programs, physical training, etc. for managing Friedreich’s ataxia was stopped during the lockdown. For instance, as per the electronic survey done amongst Friedreich ataxia (FA) patients in Italy and issued in the Cerebellum & Ataxias journal, an open access scientific journal in January 2021, it was found that the number of patients undertaking physiotherapy was declined by 72.2% due to the COVID-19 lockdown. As per the same source, more than 60% of Friedreich ataxia patients described worsening of their health in lack of physiotherapy during COVID-19 lockdown.
Drug Class Insights
On the basis of drug class, the ACE inhibitors leads the market with the maximum share in due to higher safety and it decreases the burden of the heart, and pacemakers or medicines can stabilize an arrhythmic heartbeat.
End User Insights
On the basis of the end user, the hospitals segment accounts for the maximum growth of the Friedreich’s Ataxia market. The several management activities such as speech therapy, physical therapy, occupational therapy, and surgery are conducted in the hospitals. Moreover, people prefer hospitals over other medication centers due to availability of better infrastructure and equipment.
Region Insights
North America accounts for the maximum market share owing to the increasing awareness for Friedrich’s ataxia and growing funding activities by the U.S. FDA to speed up the research activities aiming rare diseases.
Europe is also projected to grow owing to increasing initiative by market companies and the climbing number of orphan drug descriptions to a drug developed for occasional disease treatment.
Asia-Pacific is expected to grow at the fastest rate owing to rising patients focus concerning effective disease diagnosis and growing government focus for the growth of pharmaceutical industries.
Key Companies Insights
The market for Friedreich’s Ataxia is moderately competitive. With the rising applications of Friedreich’s Ataxia, new players are considering to enter the market. The companies are also involved in activities like joint ventures, mergers, acquisitions, partnerships, and collaborations. These activities aid in growing the effect of the players in the Friedreich’s Ataxia market, ultimately boosting the market growth. Some of the key companies working in the global Friedreich’s Ataxia market include:
· Reata Pharmaceuticals, Inc.
· Retrotope Inc.
· Minoryx, PTC Therapeutics
· Design Therapeutics, Inc.
· Larimar Therapeutics, Inc.
· Jupiter Neurosciences, Inc.
· Lexeo Therapeutics
· Zydus Lifesciences Ltd.
· Cipla Limited
· GlaxoSmithKline Plc.
· Aurobindo Pharma Ltd.
· Sun Pharmaceutical Industries Ltd.
· Torrent Pharmaceuticals Ltd.
· Intas Pharmaceuticals Ltd.
· Other players
Some of the Recent Developments:
· In February 2022, Design Therapeutics, Inc. announced that it is currently conducting Phase 1 clinical trial of its investigational drug DT-216, an intravenous (IV) injection for the cure of Friedreich's Ataxia.
· In March 2022, Stealth BioTherapeutics Inc. received Orphan Drug Designation from the U.S. Food and Drug Administration (US FDA) Office of Orphan Products Development for its drug Elamipretide, which is designated for the treatment of Friedreich's ataxia.
Segments
By Drug Class
· ACE Inhibitors
· Beta Blockers
· Diuretics
· Para-Benzoquinone
· Others
By Route of Administration
· Oral
· Injectable
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
By End User
· Clinics
· Hospitals
· Diagnostic Centers
· Others
Global Friedreich Ataxia Market: Regional AnalysisWe Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached Straits Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2028.
Only Three Thousand Nine Hundred Fifty US dollar
Only Four Thousand Nine Hundred Fifty US dollar
Only Five Thousand Nine Hundred Fifty US dollar